Political economy study finds COVID-19 “imbalance”
During the COVID-19 pandemic the rate of technology acceleration was remarkable, and many communities across the globe were able to benefit from this. However, this rapid development was often exclusive to resource-rich areas. A 2023 paper in Health and Place explores...
AI algorithms to support vaccine development for Disease X
In June 2023 CEPI and the Institute for Drug Discovery at Leipzig University announced a partnership to speed up the development of vaccines against future threats. Using the Rosetta Macromolecular Modelling platform, the aim is to expand artificial intelligence (AI)...
Epigraph algorithm enables swine flu vaccine research
Researchers in Nebraska believe they are getting closer to an effective and potentially universal vaccine for swine flu. With results of a study published
MOST POPULAR THIS MONTH
EU grant advances universal DeltaFLU vaccine development
A grant of €7.6 million from the European Union will contribute to the efforts of a consortium of academic and industry partners that is advancing the development of a universal influenza vaccine. The FLUniversal programme will set out to conduct clinical trials of...
DRIVing vaccine innovation with Dr Sandeep Patel
Our next interview from the Congress last month was a recorded conversation with BARDA's Dr Sandeep Patel. Dr Patel joined us for the Biodefence workshop, presenting a session before moderating a panel. We were glad that he made time to join us and give an insight...
CEPI and aVaxziPen partner on vaccine delivery for access
CEPI and aVaxziPen Ltd announced in June 2023 that they are partnering to advance the development of two vaccine candidates that use aVaxziPen’s solid-dose vaccine delivery platform. CEPI is set to provide up to $1.6 million to establish proof-of-concept for...
Moderna and Merck announce positive DMFS results from trial
In June 2023 Moderna and Merck, who have been collaborating on a Phase IIb study to evaluate mRNA-4157 (V940), announced distant metastasis-free survival (DMFS) results. The trial investigates the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, with an...
Novavax and Gates partner for adjuvant in vaccine research
Novavax announced in June 2023 that it has signed a three-year agreement with the Bill and Melinda Gates Medical Research Institute to provide its Matrix-M™ adjuvant for use in preclinical vaccine research. The adjuvant is an element of Novavax’s COVID-19 vaccine and...
VaxEquity and CPI announce Innovate UK manufacturing grant
In June 2023 VaxEquity and CPI announced a grant of around £700k from Innovate UK, which will fund a collaborative project to advance RNA vaccines and therapeutics manufacturing. VaxEquity is a UK-based biotechnology company dedicated to the development of...
Transgene presents positive cancer vaccine data for HPV
French-based biotechnology company Transgene announced in June 2023 that new data confirm that its novel investigational therapeutic cancer vaccine can induce immune responses against HPV16. The results are presented in a poster at the American Society of Clinical...
Meeting unmet medical needs with Valneva’s Thomas Lingelbach
Next in our series of conversations with experts at the World Vaccine Congress last month is founding CEO of Valneva, Thomas Lingelbach. Thomas joined us for a conversation about the many field-leading vaccines that his team is working on. We were glad to secure some...
LATEST
Strategies from a cross-sector workshop at WVC – Together we can achieve & maintain vaccination coverage
Global disruptions to routine vaccination occurred during the COVID-19 pandemic setting vaccination programs back decades, risking future disease outbreaks
Planetary health meets public health: Dr Alex Dehgan
At the Congress in Washington last month we were lucky to meet Conservation X Labs CEO and co-founder, Dr Alex Dehgan. He joined us at the event
Access through innovation: Dr Carmen Ledesma-Feliciano
Our next conversation from the Congress last month is an interview with PharmaJet’s Dr Carmen Ledesma-Feliciano. Dr Ledesma-Feliciano joined us for a
Geo-diversification of vaccines: CEPI’s Dr Matthew Downham
Next in our interview series is CEPI’s Dr Matthew Downham, who joined us at the Congress for a plenary session and a panel.
Diseases are “not done with us”, says Dr Ofer Levy
Our next interviewee is Dr Ofer Levy of Boston Children’s Hospital; he joined us in Washington for several sessions to explore adjuvants and immune profiling
Animal diseases are “red flags” says Professor James Roth
As part of our series of conversations with experts at the Congress in Washington last month we were lucky to meet Professor James Roth for an interview
VIDEOS
World Vaccine Congress Europe 2022: meet our partners!
At the World Vaccine Congress we are counting down the days to our Congress in Europe, 2022. If you haven't yet bought your tickets there is still time! With under a week to go we are pleased to share a list of supporting partners. You might see some familiar names......
World Vaccine Congress Europe 2022: Chats with Chaudhrey
With just over a week to go until the World Vaccine Congress in Europe 2022, our editor Charlotte was asked to speak to Rizwan Chaudhrey for his YouTube series, #ChatsWithChaudrey. To hear their conversation watch the video below or head to his YouTube channel! If you...
World Vaccine Congress Europe 2022: meet our exhibitors!
We hope you are looking forward to our World Vaccine Congress in Barcelona, 2022; we certainly are! We are pleased to tease some of the amazing exhibitors who will be in attendance in this short video. If you are interested in learning more about exhibiting then...
THERAPEUTIC
Moderna and Merck announce positive DMFS results from trial
In June 2023 Moderna and Merck, who have been collaborating on a Phase IIb study to evaluate mRNA-4157 (V940), announced distant metastasis-free survival (DMFS)
Transgene presents positive cancer vaccine data for HPV
French-based biotechnology company Transgene announced in June 2023 that new data confirm that its novel investigational therapeutic cancer vaccine
T cells and cancer immunosuppression: Dr Jay Berzofsky
Our next interview is with Dr Jay Berzofsky, Chief of the Vaccine Branch at NCI’s Centre for Cancer Research. He joined us at the Congress
“Vaccines are the great levelling field”, says Dr Nora Disis
At the World Vaccine Congress last month we were lucky to meet Dr Nora Disis of the University of Washington (UW), an expert in oncology.
PDAC progress with personalised RNA neoantigen vaccines
An article in Nature in May 2023 presents work from a collaboration between Genentech, Memorial Sloan Kettering Cancer Centre (MSKCC), and BioNTech.
TECHNOLOGY
Epigraph algorithm enables swine flu vaccine research
Researchers in Nebraska believe they are getting closer to an effective and potentially universal vaccine for swine flu. With results of a study published
AI algorithms to support vaccine development for Disease X
In June 2023 CEPI and the Institute for Drug Discovery at Leipzig University announced a partnership to speed up the development of future vaccines
EU grant advances universal DeltaFLU vaccine development
A grant of €7.6 million from the EU will contribute to the efforts of a consortium of academic and industry partners that is advancing a universal flu vaccine.
DRIVing vaccine innovation with Dr Sandeep Patel
Our next interview from the Congress last month was a recorded conversation with BARDA’s Dr Sandeep Patel. Dr Patel joined us for the Biodefence workshop
CEPI and aVaxziPen partner on vaccine delivery for access
CEPI and aVaxziPen Ltd announced in June 2023 that they are partnering to advance the development of two vaccine candidates that use aVaxziPen’s
INFECTION
Meeting unmet medical needs with Valneva’s Thomas Lingelbach
Next in our series of conversations with experts at the Congress last month is founding CEO of Valneva, Thomas Lingelbach.
Planetary health meets public health: Dr Alex Dehgan
At the Congress in Washington last month we were lucky to meet Conservation X Labs CEO and co-founder, Dr Alex Dehgan. He joined us at the event
Mpox, like COVID-19, no longer a PHEIC says WHO
Just days after the COVID-19 pandemic was declared no longer a public health emergency of international concern (PHEIC), mpox has followed suit.
NIH funds research into coronaviruses after 3-year pause
After the “termination and suspension” of a grant awarded in 2019, NIH and EcoHealth Alliance have announced a grant to research zoonotic coronaviruses.
“Sentinels around the globe”: meeting the Integrum team
In 2018 Integrum Scientific was formed by a “group of global innovators” in response to “the need to address the deficiencies” and “broaden the benefits”
GLOBAL HEALTH
Political economy study finds COVID-19 “imbalance”
During the COVID-19 pandemic the rate of technology acceleration was remarkable, and many communities across the globe were able to benefit from this.
Strategies from a cross-sector workshop at WVC – Together we can achieve & maintain vaccination coverage
Global disruptions to routine vaccination occurred during the COVID-19 pandemic setting vaccination programs back decades, risking future disease outbreaks
Geo-diversification of vaccines: CEPI’s Dr Matthew Downham
Next in our interview series is CEPI’s Dr Matthew Downham, who joined us at the Congress for a plenary session and a panel.
Animal diseases are “red flags” says Professor James Roth
As part of our series of conversations with experts at the Congress in Washington last month we were lucky to meet Professor James Roth for an interview
Agricultural equilibrium: old meets new with Joel Harris
Our next interview guest from the Congress last month is Genvax Technologies’ CEO and Co-Founder, Joel Harris. Joel joined us for a presentation and a panel
